Clinical trials: Genital Neoplasms, Male
Prostate Cancer
PRO-MR-RT Systematic Patient-reported Outcomes to Pelvic Online MRgRT
In 2018 the Unity MR-linac was approved for treating patients with online magnetic resonance (MR)-guided radiotherapy. With the MR-linac it is possible to get real-time MR images with high soft tissue contrast, adapt the…
- Trial name
- NCT05615909
- Testing
- Online MR-guided radiotherapy, CT-guided radiotherapy
- Where
- Denmark
- Volunteers
- 156 people
- Sponsor
- Odense University Hospital
Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with prostate cancer that has come back (recurrent).
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03371719
- Testing
- Apalutamide, External Beam Radiation Therapy
- Where
- 360 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- NRG Oncology
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer, Fatigue
Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
Background: Fatigue is a common side effect of cancer and its treatment. Up to 96% of patients with cancer have fatigue. The cause of fatigue in people with cancer or those receiving treatment is poorly understood, making fatigue…
- Conditions
- Cancer, Fatigue, Prostate Cancer, Breast Cancer
- Trial name
- NCT01231932
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- National Institute of Nursing Research (NINR)
Prostate Cancer
Pilot Study of Dose Escalation in Prostate Radiotherapy Using the MR-Linac (DESTINATION-MRL)
This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated/de-escalated dose directed by MRI) 5 fraction SBRT to the…
- Trial name
- DESTINATION-MR (NCT06177093)
- Testing
- MR Linac delivered Radiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Pilot Study on Focal Prostate Radio-Frequency Ablation
This is a prospective pilot study. The purpose of this research study is to evaluate the safety and efficacy of focal Radio-Frequency Ablation (RFA) in men with low-risk, clinically localized prostate cancer.
- Trial name
- NCT01423006
- Testing
- Radio-Frequency Ablation (RFA) ENCAGE™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.
- Trial name
- FLUPROSTIC (NCT01501630)
- Testing
- performance of PET/CT and whole-body MRI
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urothelial Carcinoma Bladder, Sperm Count, Low
Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBC
To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.
- Conditions
- Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis, Non Muscle Invasive Bladder Cancer
- Trial name
- NCT05701332
- Testing
- Bacillus Calmette Guerin, Gemcitabine HCL (Gemzar)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Assiut University
Prostate Cancer
Implementation of Precision Medicine in High-risk Prostate Cancer
This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients.
- Trial name
- SPRINTR-REAL (NCT06687421)
- Testing
- High-risk treatment SOC, Active monitoring, Radical prostatectomy
- Where
- Sweden
- Volunteers
- 5,500 people
- Sponsor
- Andreas Josefsson
Carcinoma, Renal Cell, Prostatic Neoplasms
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable…
- Trial name
- NCT00106301
- Testing
- FK228 (romidepsin)
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Celgene
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Prostate Cancer
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
This is a two-tiered pilot study in which there will be no randomization and no placebo treatment. This study will be to perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if…
- Trial name
- NCT04698564
- Testing
- Hyperpolarized 13C-Pyruvate
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy
This is a phase I, dose selection study of safety and effect of different doses of TENDU vaccine, a therapeutic peptide conjugate vaccine, in patients with relapse after primary radical prostatectomy.
- Trial name
- NCT04701021
- Testing
- TENDU
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Ultimovacs ASA
Prostate Cancer
Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies
The STHLM3-MRI trial is a study comparing traditional prostate cancer detection using PSA and systematic biopsies with the improved pipeline for prostate cancer detection using the STHLM3 test and targeted biopsies in a screening…
- Trial name
- STHLM3MR-2 (NCT03377881)
- Testing
- MRI/Fusion biopsies, Systematic biopsies
- Where
- 3 sites in Sweden
- Volunteers
- 12,750 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Breast Cancer, Prostate Cancer
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
- Trial name
- NCT03383107
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Recurrent Prostate Cancer
Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the…
- Trial name
- BAT (NCT01750398)
- Testing
- Testosterone cypionate, Goserelin, Leuprolide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Blood Pressure, Hypertension
Hypertension Management in Cancer Patients
The investigators propose to leverage new technology using the Qardio app for iPhone and Android devices to automatically upload blood pressures, using a well-validated blue tooth blood pressure monitor (QardioArm), directly into…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- NCT03919214
- Testing
- Automated Messaging
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.